Literature DB >> 35905821

An experimental evaluation of the efficacy of perinatal sulforaphane supplementation to decrease the incidence and severity of vinclozolin-induced hypospadias in the mouse model.

Ciro M Amato1, Ariel Fricke1, Sahiti Marella1, Joshua P Mogus1, Michael Bereman2, Krista A McCoy3.   

Abstract

Determining the mechanisms of toxicity induced by pollutants has long been a research priority in lieu of considering the mechanisms of resilience that prevent deleterious impacts. Protective mechanisms in many taxa can be therapeutically targeted to enhance resilience to synthetic toxicants. For example, the environmental sensor, Nuclear factor (erythroid-derived 2)-like 2 (Nfe2l2 or Nrf2), a transcription factor, facilitates transcription of many protective genes. Hypospadias is a common malformation of the penis. The risk of being born with hypospadias increases with pollutant exposure. We use vinclozolin-induced hypospadias in the mouse as a model to test the hypothesis that pollutant-induced birth defects can be prevented and reduced in severity by augmenting natural mechanisms of resilience. Pregnant mice were exposed to the demasculinizing toxicant, vinclozolin, in combination with increasing doses of the NRF2 activator, sulforaphane. The sulforaphane dose that most effectively increased masculinization (anogenital distance) was identified and used to test the hypothesis that sulforaphane reduces the hypospadias-inducing potency of vinclozolin. Finally, a Nrf2 knockout study was conducted to test whether NRF2 was required for the sulforaphane-induced rescue effects. Sulforaphane supplementation to vinclozolin exposed embryos increased anogenital distance in a nonlinear fashion typical of Nrf2 activators. The most effective dose of sulforaphane (45 mg/kg) reduced the occurrence and severity of vinclozolin-induced hypospadias and corrected penis morphogenesis. The sulforaphane-induced rescue effect was dependent on the presence of Nrf2. Nrf2 plays a critical role in protecting the fetus from vinclozolin and reduces the incidence and severity of hypospadias, the most common birth defect in boys in many countries. This work lays a foundation for developing prenatal supplements that will protect the fetus from pollutant-induced hypospadias. Studying the protective mechanisms that drive resilience to toxicants will facilitate innovation of protective therapies.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Birth defects prevention; Hypospadias; Mechanisms of resilience; Preventive toxicology; Sulforaphane; Vinclozolin

Mesh:

Substances:

Year:  2022        PMID: 35905821      PMCID: PMC9450412          DOI: 10.1016/j.taap.2022.116177

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.460


  46 in total

1.  The development of the male genitourinary system: III. The formation of the spongiose and glandar urethra.

Authors:  P J Hynes; J P Fraher
Journal:  Br J Plast Surg       Date:  2004-04

2.  Genetic variation in the Nrf2 promoter associates with defective spermatogenesis in humans.

Authors:  Bolan Yu; Huanlan Lin; Lixia Yang; Kang Chen; Haihua Luo; Jianqiao Liu; Xingcheng Gao; Xuefeng Xia; Zhaofeng Huang
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

3.  Steroid receptor profiling of vinclozolin and its primary metabolites.

Authors:  José-Manuel Molina-Molina; Anne Hillenweck; Isabelle Jouanin; Daniel Zalko; Jean-Pierre Cravedi; Mariana-Fátima Fernández; Arnaud Pillon; Jean-Claude Nicolas; Nicolás Olea; Patrick Balaguer
Journal:  Toxicol Appl Pharmacol       Date:  2006-06-05       Impact factor: 4.219

4.  Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer.

Authors:  Chi-Chen Hong; Christine B Ambrosone; Jiyoung Ahn; Ji-Yeob Choi; Marjorie L McCullough; Victoria L Stevens; Carmen Rodriguez; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-08-28       Impact factor: 4.254

5.  Is Hypospadias Associated with Prenatal Exposure to Endocrine Disruptors? A French Collaborative Controlled Study of a Cohort of 300 Consecutive Children Without Genetic Defect.

Authors:  Nicolas Kalfa; Françoise Paris; Pascal Philibert; Mattea Orsini; Sylvie Broussous; Nadège Fauconnet-Servant; Françoise Audran; Laura Gaspari; Hélène Lehors; Myriam Haddad; Jean-Michel Guys; Rachel Reynaud; Pierre Alessandrini; Thierry Merrot; Kathy Wagner; Jean-Yves Kurzenne; Florence Bastiani; Jean Bréaud; Jean-Stéphane Valla; Gérard Morisson Lacombe; Eric Dobremez; Amel Zahhaf; Jean-Pierre Daures; Charles Sultan
Journal:  Eur Urol       Date:  2015-05-23       Impact factor: 20.096

6.  First trimester phthalate exposure and anogenital distance in newborns.

Authors:  S H Swan; S Sathyanarayana; E S Barrett; S Janssen; F Liu; R H N Nguyen; J B Redmon
Journal:  Hum Reprod       Date:  2015-02-18       Impact factor: 6.918

7.  Sulforaphane Bioavailability and Effects on Blood Pressure in Women with Pregnancy Hypertension.

Authors:  A G Langston-Cox; D Anderson; D J Creek; K R Palmer; S A Marshall; E M Wallace
Journal:  Reprod Sci       Date:  2021-01-06       Impact factor: 3.060

8.  Sulforaphane reduces obesity by reversing leptin resistance.

Authors:  Işın Çakır; Pauline Lining Pan; Colleen K Hadley; Abdulrahman El-Gamal; Amina Fadel; Dina Elsayegh; Omnia Mohamed; Nasser M Rizk; Masoud Ghamari-Langroudi
Journal:  Elife       Date:  2022-03-24       Impact factor: 8.140

Review 9.  Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality?

Authors:  Christine A Houghton; Robert G Fassett; Jeff S Coombes
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

Review 10.  In utero exposure to endocrine disruptors and developmental neurotoxicity: Implications for behavioural and neurological disorders in adult life.

Authors:  Glancis Luzeena Raja; K Divya Subhashree; Kamalini Esther Kantayya
Journal:  Environ Res       Date:  2021-08-03       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.